medigraphic.com
ISSN 0188-2198 (Print)

2013, Number 4

<< Back

Rev Mex Cardiol 2013; 24 (4)

Association Levels of brain natriuretic peptide with morbidity and mortality in infective endocarditis

Jáuregui RO, Galván GE, Machain LCZ

Language: Spanish
References: 28
Page: 196-204
PDF size: 217.80 Kb.


ABSTRACT

Infective endocarditis (IE) is an infection with high morbidity and mortality. Identify patients with increased risk for complications, provides the opportunity to establish an aggressive therapeutic. B-type natriuretic peptide is a quick, available and high levels has been linked with poor outcome in IE. Objectives: To determine the association between B-type natriuretic peptide levels and morbidity and mortality in patients with infective endocarditis. Material and methods: We included patients ≥ 15 years, during the period July 2010 to July 2012. They were divided into groups based on the levels of B-type natriuretic peptide, group 1 B-type natriuretic peptide ‹ 400 pg/mL, group 2 B-type natriuretic peptide ≥ 400 ‹ 1,000 pg/mL and group 3 ≥ 1,000 pg/mL. The association between elevated B-type natriuretic peptide and a composite outcome of death and embolic was evaluated as a primary endpoint and these components individually as a secondary points. Descriptive statistics were employed measures of central tendency and dispersion. Statistical significance was evaluated using p Pearson and χ2 test. Results: We included 57 patients, 23 (40.4%) in the group 1; 21 (36.8%) to group 2, and 13 (22.8%) in the group 3. The primary point (composite of death and embolic events) was higher in group 3 (57.1%) compared with group 1 (0%) and 2 (42.9%), p = 0.024. The secondary endpoints evaluated individually, in-hospital mortality was higher in group 3 (75%), p ‹ 0.0001. Late mortality was present in one patient in group 2, p = 0.41. Embolic events were more frequent in group 2 (57.9%) p = 0.020. Conclusions: This study demonstrates the association between elevated B-type natriuretic peptide and increased morbidity and mortality in patients with infective endocarditis.


REFERENCES

  1. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. Eur Heart J. 2009; 30: 2369-2413.

  2. Hoen B, Alla F, Selton-Suty C et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002; 288: 75-81.

  3. Thuny F, Di Salvo G, Belliard O et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005; 112: 69-75.

  4. San Román JA, López J, Vilacosta I et al. Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med. 2007; 120: 369 e1-e7.

  5. Chu VH, Cabell CH, Benjamin DK Jr et al. Early predictors of in-hospital death in infective endocarditis. Circulation. 2004; 109: 1745-1749.

  6. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009; 169: 463-473.

  7. Thuny F, Di Salvo G, Belliard O et al. Risk of embolism and death in infective endocarditis. Prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005; 112: 69-75.

  8. Evangelista A, González-Alujas MT. Echocardiography in infective endocarditis. Heart. 2004; 90: 614-617.

  9. Cabell CH, Pond KK, Peterson GE et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J. 2001; 142: 75-80.

  10. Watkin RW, Lang S, Smith JM et al. Role of troponin I in active infective endocarditis. Am J Cardiol. 2004; 94: 1198-1199.

  11. Purcell JB, Patel M, Khera A et al. Relation of troponin elevation to outcome in patients with infective endocarditis. Am J Cardiol. 2008;101:1479-1481.

  12. Tsenovoy P, Aronow WS, Joseph J et al. Patients with infective endocarditis and increased cardiac troponin I levels have a higher incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels. Cardiology. 2009; 112: 202-204.

  13. Stancoven AB, Shiue AB, Khera A, Pinkston K et al. Association of Troponin T, detected with highly sensitive assay, and outcomes in infective endocarditis. Am J Cardiol. 2011; 108: 416-420.

  14. Kahveci G, Bayrak F, Mutlu B et al. Clinical Significance of high-density lipoprotein cholesterol in left-sided infective endocarditis. Am J Cardiol. 2008; 101: 1170-1173.

  15. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002; 105: 2392-2397.

  16. Koglin J, Pehlivanli S, Schwaiblmair M et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001; 38: 1934-1941.

  17. Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43: 635-641.

  18. Fonarow GC, Peacock WF, Phillips CO et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007; 49: 1943-1950.

  19. Arakawa N, Nakamura M, Aoki H et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol. 1996; 27: 1656-1661.

  20. Omland T, Aakvaag A, Bonarjee VVS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93: 1963-1969.

  21. De Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014-1021.

  22. Kandil E, Burack J, Sawas A et al. B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg. 2008; 143: 242-246.

  23. Brueckmann M, Huhle G, Lang S et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation. 2005; 112: 527-534.

  24. Post F, Weilemann LS, Messow C-M et al. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med. 2008; 36: 3030-3037.

  25. Parrillo JE, Burch C, Shelhamer JH et al. A circulating myocardial depressant substance in humans with septic shock.

  26. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest. 1985; 76: 1539-1553.

  27. Shiue AB, Stancoven AB, Purcell JB et al. Relation of level of B-Type natriuretic peptide with outcomes in patients with infective endocarditis. Am J Cardiol. 2010; 106: 1011-1015.

  28. Kahveci G, Bayrak F, Mutlu B et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. Am J Cardiol. 2007; 99: 1429-1433.




2020     |     www.medigraphic.com